Cargando…

Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells

In patients with primary biliary cholangitis (PBC), the serum liver biochemistry measured during treatment with ursodeoxycholic acid—the UDCA response—accurately predicts long-term outcome. Molecular characterization of patients stratified by UDCA response can improve biological understanding of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulcahy, Victoria, Liaskou, Evaggelia, Martin, Jose-Ezequiel, Kotagiri, Prasanti, Badrock, Jonathan, Jones, Rebecca L., Rushbrook, Simon M, Ryder, Stephen D., Thorburn, Douglas, Taylor-Robinson, Simon D., Clark, Graeme, Cordell, Heather J., Sandford, Richard N., Jones, David E., Hirschfield, Gideon M., Mells, George F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079354/ https://www.ncbi.nlm.nih.gov/pubmed/37026715 http://dx.doi.org/10.1097/HC9.0000000000000110

Ejemplares similares

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study
por: Jones, David E.J., et al.
Publicado: (2022)

Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity
por: Liaskou, Evaggelia, et al.
Publicado: (2019)

The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis
por: Dyson, J. K, et al.
Publicado: (2016)

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis–Inflammatory Bowel Disease
por: Chung, Brian K., et al.
Publicado: (2018)

Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis
por: Darlay, Rebecca, et al.
Publicado: (2018)

Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis
por: Chen, Yung-Yi, et al.
Publicado: (2019)

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
por: Chapman, Michael Huw, et al.
Publicado: (2019)

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
por: Hirschfield, Gideon M, et al.
Publicado: (2018)

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
por: Goode, Elizabeth C., et al.
Publicado: (2019)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System
por: Burke, Laura, et al.
Publicado: (2022)

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
por: Cordell, Heather J., et al.
Publicado: (2021)

Clinical application of the GLOBE and United Kingdom‐primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis
por: Carbone, Marco, et al.
Publicado: (2018)

Innate Immune Cells in Liver Inflammation
por: Liaskou, Evaggelia, et al.
Publicado: (2012)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]
por: Cordell, Heather J., et al.
Publicado: (2022)

Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals
por: Liaskou, Evaggelia, et al.
Publicado: (2017)

Soluble immune checkpoints are elevated in patients with primary biliary cholangitis
por: Gao, Xiuzhu, et al.
Publicado: (2023)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
por: Wetten, Aaron, et al.
Publicado: (2022)

Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
por: Montali, Lorenzo, et al.
Publicado: (2021)

Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging
por: Grover, V. P. B., et al.
Publicado: (2016)

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
por: Mayo, Marlyn J., et al.
Publicado: (2019)

Distinct immune surveillance in primary biliary cholangitis and primary sclerosing cholangitis is linked with discrete cholangiocarcinoma risk
por: Nanjundappa, Roopa H., et al.
Publicado: (2023)

Effect of LncRNA XIST on Immune Cells of Primary Biliary Cholangitis
por: She, Chunhui, et al.
Publicado: (2022)

Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis
por: Schultheiß, Christoph, et al.
Publicado: (2023)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner
por: Trivedi, Palak J, et al.
Publicado: (2018)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
por: Harms, Maren H., et al.
Publicado: (2020)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis
por: Dyson, Jessica Katharine, et al.
Publicado: (2020)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways
por: Cordell, Heather J., et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis
por: Wang, Chang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upn0263b5l0sst3tujq3r1adcr